Yellow Fever Vaccine

Sayenna Uduman
Visiting Professor, Infection Control Committee & ID Division of the KIMS
Thiruvananthapuram, Kerala, India

First Created: 04/13/2016  Last Updated: 12/27/2023

Key Information

  • Yellow Fever (YF) virus is transmitted to humans through the bite of an infected mosquito causing acute febrile hemorrhagic illness.

  • YF disease is endemic and intermittently epidemic in sub-Saharan Africa and tropical South America and not in Asia.

  • YF is a vaccine-preventable disease and the vaccine is highly immunogenic. It is a safe vaccine. The protective immunity persists for more than 10 years following vaccination.

  • Routine YF vaccination is not recommended in India but considered for certain groups of people.

  • YF vaccine is given only at approved vaccination centers. International health regulations have set the requirements for proof of YF vaccination when traveling to specific endemic countries.

Virology & Epidemiologic Backgrounds

Yellow fever (YF) is a mosquito-borne acute viral hemorrhagic disease caused by an RNA virus from the family of Flaviviridae. Mosquitoes become infected with the virus when they bite an infected human and non-human primates. The virus is transmitted to humans through the bite of an infected mosquito, primarily by the Aedes aegypti female mosquito. The incubation period is 3 to 6 days. Humans infected with YF virus experience the highest levels of viremia and are infectious to mosquitoes shortly before the onset of fever and for 3 to 5 days afterward

YF occurs year-round, predominantly in rural areas of sub-Saharan Africa (32 countries) and South America (13 countries), but not in Asia. In endemic areas, where the virus is present in monkeys is a potential risk to humans. Sustained transmission is not possible in India because the recognized mosquito vectors & the potential reservoirs are not present.

Spectrum of Clinical Illness

Clinical presentation varies in severity from asymptomatic to fatal. When symptomatic, YF is typically characterized by an acute onset of an undifferentiating febrile flu-like illness. In about 85% of cases, the disease resolves when the acute symptoms subside. For others, after a brief remission lasting anywhere between hours to a day, symptoms worsen, and the disease advances, eventually leading to renal failure, hemorrhagic symptoms, and thrombocytopenia. Treatment is symptomatic and supportive. The WHO estimates, an estimated 200,000 people become infected each year, with up to 30,000 deaths annually. Older adults and those with compromised immune systems are most at risk for serious complications.

Risk Factors for a Traveler Acquiring YF Disease

This depends upon various factors that would include: immunization status, use of personal protection measures against mosquito bites, travel history & location, duration of exposure, the local rate of virus transmission, and activities while traveling. The risk for acquiring YF is low for most travelers, particularly those staying in highly developed major urban areas.


Vaccine Preventable Disease

A fatal case of YF continues to be reported among unimmunized travelers to endemic regions; vaccination is the only way to prevent YF disease. Those who live in areas populated by infected mosquitoes and those who haven’t been vaccinated for YF are at risk. Prevention measures against YF should include, also protection against mosquito bites.

YF vaccine is a live-attenuated virus (17D strain) by serial passages in chicken embryo tissue culture. The vaccine preparation is lyophilized, kept under cold-chain conditions, and is considered extremely safe. A single-dose administration (subcutaneous or intramuscular) provides protection for at least 10 years or longer. More than 80% of persons immunized develop neutralizing antibodies 10 days after vaccination and more than 99% by 28 days after vaccination and immunity persists >10 years. A booster dose after 10 years is recommended for those who continue to live or travel in endemic areas. YF vaccine may be given at the same time as most other vaccines. The side effects are benign and transient in nature; may include a low-grade fever, mild headache, and fatigue.

The Centers for Disease Control (CDC) recommends for all people 9 months or older traveling to or from certain countries with an endemic disease or those living in those regions. Nursing mothers traveling with an infant who is 6 to 8 months old should either postpone travel to these areas if possible or talk to your doctor about vaccination. The decision to immunize infants below 9 months of age must balance the risk of exposure with the risk of vaccine-associated encephalitis at this vulnerable specific age group.

The IAP Advisory Committee on Vaccines & Immunization Practices 2013 -14 (the ACVIP) recommends the YF vaccine for high-risk category children under special circumstances. India imports the YF vaccine to overcome vaccine shortages and the vaccine is available only at the designated center. One should refer to the website for an updated list of Government Yellow Fever Vaccination Centers with contact information. For complete prescribing information, consult the product leaflet or information contained within Health Ministry authorized product monographs. (

YF is unique among diseases in that there are international health regulations which outline the requirements for proof of vaccination when traveling to specific areas. In recent months, the WHO placed the southern African countries like Zambia and Namibia on high alert because of a ‘worst YF outbreak in 30 years’ occurring at the present time. Many of these, and other countries, will demand a YF certificate from travelers as a condition of entry to their country. Individuals planning to travel internationally and for more detailed information on the YF vaccine, including adverse events, precautions, and contraindications visit the CDC website (

In summary:

  • YF is a serious febrile hemorrhagic illness with dreadful complications and it is a vaccine preventable disease.

  • Apart from vaccination, disease prevention measures should include personnel protection against mosquito bites.

  • Under regulations set out by the WHO, anyone travelling to a country or area where there is a risk of contracting YF disease, must have an International Certificate of Vaccination, before travelling.


The vaccine is contraindicated in people who have an allergic reaction to eggs or chicken proteins and in people who are immunocompromised. YF vaccine, like all live-virus vaccines, should be avoided during pregnancy. Pregnancy and breastfeeding are precautions to yellow fever vaccine administration because rare cases of in utero or breastfeeding transmission of the vaccine virus have been documented. Refer Table for vaccination precautions and contraindications.

Table: Precautions and Contraindications to vaccine Administration

Precautions Contraindications
Age 6 through 8 mon. and =60 yrs. of age Infants less than 6 mon. of age
Pregnancy Primary immunodeficiency’s
*Nursing mothers (breast feedings) Malignancy, Post Transplantations
Asymptomatic HIV infection Symptomatic HIV infection or CD4+ T-lymphocyte count <200/mm
  Those who are on immunosuppressive and immune-modulatory therapies
* Meningoencephalitis has been reported in neonates (8 days and 38 days old) exposed to vaccine virus
through breastfeeding. Administration of YF vaccine should be delayed in breastfeeding women until infants are
at least 6 months of age unless exposure to YF is unavoidable.

1. Centers for Disease Control and Prevention. Yellow fever vaccine. Recommendations of the Advisory Committee on Immunization Practices. MMWR Recomm Rep. 2010; 59(RR-07):1–27.
3. IAP (ACVIP) Guidebook on Immunization 2013–14.

Yellow Fever Vaccine Yellow Fever Vaccine 2023-12-27
Disclaimer: The information given by is provided by medical and paramedical & Health providers voluntarily for display & is meant only for informational purpose. The site does not guarantee the accuracy or authenticity of the information. Use of any information is solely at the user's own risk. The appearance of advertisement or product information in the various section in the website does not constitute an endorsement or approval by Pediatric Oncall of the quality or value of the said product or of claims made by its manufacturer.
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0